TITLE

Hot-Topic Roundup

PUB. DATE
October 2012
SOURCE
Pharmaceutical Technology;Oct2012, Vol. 36 Issue 10, p30
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to the pharmaceutical industry in the U.S. as of October 2012. The U.S. Food & Drug Administration (FDA) officials are trying to set standards for drugs to reduce prescription drug costs. Pharmaceutical companies are planning to strengthen their position in the orphan-drug market considering it a source of growth. FDA has launched a new program to increase transparency in industry interactions with physicians and prescribers.
ACCESSION #
83005419

 

Related Articles

  • WEEK IN WASHINGTON.  // BioWorld Insight;8/29/2011, Vol. 19 Issue 35, p6 

    The article offers news briefs related to pharmaceutical industry in the U.S. including the conflict of interest rules released by the National Institute of Health (NIH) for lower reporting threshold, the strategic plan released by the Food and Drugs Administration (FDA) for regulatory science,...

  • The Future of Orphan Drug Development. Woodcock, J // Clinical Pharmacology & Therapeutics;Aug2012, Vol. 92 Issue 2, p146 

    The article offers information on the U.S. Orphan Drug Act of 1983 which aims to increase orphan drug development. It informs that the ratio of new molecular entities (NME) is growing in the market. The U.S. Food and Drug Administration is dealing with orphan drug development program in a...

  • Age-Related Disorder. Lowe, Derek B. // Contract Pharma;Jan/Feb2013, Vol. 15 Issue 1, p30 

    The article focuses on disorders associated to aging and the discovery of drugs for these diseases by pharmaceutical companies in the U.S. It notes the scrutiny whether a drugmaker intends to sell medication for unapproved uses. It considers the ability of the Food and Drug Administration (FDA)...

  • Will medications be safer in the future? Erickson, Amy K. // Pharmacy Today;Nov2010, Vol. 16 Issue 11, p40 

    The article focuses on issues faced by the U.S. Food and Drug Administration (FDA) concerning safety and quality of drugs manufactured abroad. It highlights on the regulatory system implemented by FDA to ensure that products made outside the U.S. meet the standards of the pharmaceutical...

  • The Metrics of Quality Culture. Harrison, Andrew; Schniepp, Susan // Pharmaceutical Technology;Sep2015, Vol. 39 Issue 9, p22 

    The article discusses the guidance for quality metrics proposed by the U.S Food & Drug Administration (USFDA). Topics discussed include passage of the Food and Drug Administration Safety and Innovation Act (FDASIA) to prevent drug shortage, use of the guidance by pharmaceutical industries to...

  • Price Gouging and the Dangerous New Breed of Pharma Companies. Smith, A. Gordon // Harvard Business Review Digital Articles;7/6/2016, p2 

    The article discusses the increasing number of pharmaceutical companies that prioritize profits over drug discovery and manufacturing by acquiring legal rights to existing drugs and charging higher prices after the U.S. Food and Drug Administration approval without making research investment.

  • When the Well Runs Dry. Agres, Ted // Drug Discovery & Development;Oct2011, Vol. 14 Issue 10, p10 

    The article focuses on the bipartisan legislation requiring pharmaceutical manufacturers to provide advance notice to the Food and Drug Administration (FDA) regarding potential shortages in the U.S. It notes that the Preserving Access to Life-Saving Medications Act also allows fines up to 10,000...

  • Implementing Process Validation Guidances. Calcott, Peter H. // Contract Pharma;Mar2013, Vol. 15 Issue 2, p54 

    The article discusses how to implement the Process Validation Guidances which was released by the Food and Drug Administration for the pharmaceutical industry in the U.S. It mentions that the rationale and reasoning for process validation is described in the guidance. It describes three...

  • Managing Product Supply Risks. Abraham, Sushil // Pharmaceutical Technology;Apr2012, Vol. 36 Issue 4, p102 

    The article focuses on the use of geographic diversification and legacy technology transfers to deflect drug shortage in the U.S. It mentions that the U.S. Food and Drug Administration, together with the pharmaceutical industry, were asked by U.S. President Barack Obama to provide a solution on...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics